Approvable designations; Nonapprovable designation; Fast-track designations; Priority review; Orphan drug designations
Approvable designations
Nonapprovable designation
Fast-track designations
Orphan drug designations
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.